Aslan Pharmaceuticals Pte Ltd (6497) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Aslan Pharmaceuticals Pte Ltd (Aslan), a subsidiary of Aslan Pharmaceuticals Ltd, is a biotechnology company that offers immuno-oncology agents and targeted therapies. The companys pipeline products comprise varlitinib, ASLAN002, ASLAN003 and ASLAN004. Its ASLAN002 is a small molecule inhibitor of RON and cMET receptor tyrosine kinases for the treatment of gastric and breast cancer. Aslans ASLAN003 is a small molecule inhibitor of dihydroorotate dehydrogenase inhibitor to treat tumors; and ASLAN004 is a full human monoclonal antibody that reduces exacerbation in moderate or severe asthma and improves the functioning of lungs. It operates in Singapore, Taiwan, China and Australia. Aslan is headquartered in Singapore City, Singapore.

Aslan Pharmaceuticals Pte Ltd (6497) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Aslan Pharma Raises USD23 Million in Venture Financing 12
Aslan Pharma Raises Additional USD9 Million in Venture Financing 14
Aslan Pharma Raises USD34 Million in Series C Financing 16
Aslan Pharma Raises US$22 Million In Series B Financing 18
Partnerships 20
Aslan Pharma Enters into Agreeement with Cancer Science Institute Of Singapore and National University Cancer Institute 20
Aslan Pharma Enters into MoU with National Cancer Centre Singapore 21
ASLAN Pharma Enters into Agreement with ACT Genomics 22
Licensing Agreements 23
Aslan Pharma Enters into Licensing Agreement with Array BioPharma 23
ASLAN Pharma Enters into Licensing Agreement with Nanyang Technological University 24
ASLAN Pharma Enters into Licensing Agreement with Agency for Science, Technology and Research 25
Hyundai Pharma Enters into Licensing Agreement with Aslan Pharma 26
Aslan Pharma Enters Into Licensing Agreement With CSL For CSL-334 27
Aslan Pharma Expands Licensing Agreement with Almirall for LAS186323 28
Equity Offering 29
Aslan Pharma Raises USD42.2 Million in Public Offering of Shares 29
Aslan Pharma Plans to Raise USD84 Million in Public Offering of Shares 31
Aslan Pharma Plans to Raise Funds through Private Placement of Shares 32
Aslan Pharma Raises USD33.2 Million in IPO 33
Aslan Pharmaceuticals Pte Ltd - Key Competitors 34
Aslan Pharmaceuticals Pte Ltd - Key Employees 35
Aslan Pharmaceuticals Pte Ltd - Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Financial Announcements 37
Aug 06, 2018: Aslan pharmaceuticals reports second quarter 2018 financial results and provides corporate update 37
Corporate Communications 38
Jan 23, 2017: Aslan Pharmaceuticals Receives Approval To List On Taipei Exchange 38
Product News 39
08/31/2017: ASLAN Pharmaceuticals Announces First Patient Enrolled in a Global Phase 2/3 Study for Varlitinib in Gastric Cancer 39
08/10/2018: ASLAN Pharmaceuticals completes recruitment for global phase 2 study for Varlitinib in first line gastric cancer 40
05/17/2018: ASLAN Pharmaceuticals to Present Two Posters on Varlitinib at ASCO 41
01/31/2018: ASLAN Pharmaceuticals sponsors Cholangiocarcinoma Foundation Annual Conference 2018 42
01/24/2017: Aslan Pharmaceuticals To Present At The Cholangiocarcinoma Foundation Annual Conference 2017 43
01/18/2018: ASLAN Pharmaceuticals Appoints Stephen Doyle as Head of China 44
Product Approvals 45
Aug 20, 2018: ASLAN Pharmaceuticals granted Orphan Drug Designationby the FDA for ASLAN003 for the treatment of acute myeloid leukaemia 45
Feb 19, 2017: ASLAN Pharmaceuticals receives Orphan Drug Designation in Korea for varlitinib (ASLAN001) in biliary tract cancer 46
Clinical Trials 47
Oct 09, 2018: Aslan Pharmaceuticals to present poster on Varlitinib at European Society for Medical Oncology congress 47
Sep 17, 2018: ASLAN Pharmaceuticals Provides Update on Timelines for Clinical Trial of Varlitinib in Biliary Tract Cancer in China 48
Jul 03, 2018: Aslan Pharmaceuticals Submits Clinical Trial Authorisation Application For First In Man Studies For ASLAN004 49
Apr 17, 2018: ASLAN Pharmaceuticals Announces Presentation of New Pre-Clinical Data on Varlitinib in Hepatocellular Carcinoma at AACR 50
Jan 08, 2018: ASLAN Pharmaceuticals announces shortened timeline to commercialisation for varlitinib in China 51
Jan 02, 2018: Aslan Pharmaceuticals Abstract On Varlitinib Wins Best Poster At ESMO Asia 2017 52
Nov 13, 2017: Aslan Pharmaceuticals Receives IND Approval In Singapore To Initiate Phase 2 Study Of ASLAN003 In Acute Myeloid Leukaemia 53
Nov 08, 2017: ASLAN Pharmaceuticals Announces Poster Presentation at ESMO Asia Congress 2017 54
Sep 07, 2017: Aslan Pharmaceuticals Announces Initiation Of First Clinical Study In Hepatocellular Carcinoma For Varlitinib 55
Jun 29, 2017: Aslan Pharmaceuticals Announces First Patient Enrolled In Global Pivotal Treetopp Study For Varlitinib In Biliary Tract Cancer 56
Jun 12, 2017: Aslan Pharmaceuticals Announces MTD For Varlitinib In Combination With Chemotherapies Commonly Used In First Line Gastric Cancer 57
Jun 07, 2017: Aslan Pharmaceuticals Announces New Positive Data Identifying ASLAN003 As A Novel Therapeutic Agent In Acute Myeloid Leukaemia 58
Jun 02, 2017: Aslan Pharmaceuticals Announces Publication of New Varlitinib Data in Metastatic Solid Tumours at ASCO 59
Jun 01, 2017: Aslan Pharmaceuticals Receives Clinical Trial Authorisation To Initiate Pivotal Study Of Varlitinib In Gastric Cancer 60
May 18, 2017: New Data On Varlitinib Published At 2017 Annual Meeting Of American Society Of Cancer Oncology 61
Apr 25, 2017: ASLAN Pharmaceuticals Initiates Global Pivotal Study For Varlitinib In Biliary Tract Cancer 62
Feb 13, 2017: Aslan Pharmaceuticals Announces First Patient Enrolled In Phase 1 Study Of Varlitinib In Japan 63
Feb 09, 2017: ASLAN Pharmaceuticals reports positive top-line results for phase 2 clinical trial of varlitinib in metastatic breast cancer 64
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65

List Of Tables


Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aslan Pharmaceuticals Pte Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aslan Pharma Raises USD23 Million in Venture Financing 12
Aslan Pharma Raises Additional USD9 Million in Venture Financing 14
Aslan Pharma Raises USD34 Million in Series C Financing 16
Aslan Pharma Raises US$22 Million In Series B Financing 18
Aslan Pharma Enters into Agreeement with Cancer Science Institute Of Singapore and National University Cancer Institute 20
Aslan Pharma Enters into MoU with National Cancer Centre Singapore 21
ASLAN Pharma Enters into Agreement with ACT Genomics 22
Aslan Pharma Enters into Licensing Agreement with Array BioPharma 23
ASLAN Pharma Enters into Licensing Agreement with Nanyang Technological University 24
ASLAN Pharma Enters into Licensing Agreement with Agency for Science, Technology and Research 25
Hyundai Pharma Enters into Licensing Agreement with Aslan Pharma 26
Aslan Pharma Enters Into Licensing Agreement With CSL For CSL-334 27
Aslan Pharma Expands Licensing Agreement with Almirall for LAS186323 28
Aslan Pharma Raises USD42.2 Million in Public Offering of Shares 29
Aslan Pharma Plans to Raise USD84 Million in Public Offering of Shares 31
Aslan Pharma Plans to Raise Funds through Private Placement of Shares 32
Aslan Pharma Raises USD33.2 Million in IPO 33
Aslan Pharmaceuticals Pte Ltd, Key Competitors 34
Aslan Pharmaceuticals Pte Ltd, Key Employees 35
Aslan Pharmaceuticals Pte Ltd, Other Locations 36
Aslan Pharmaceuticals Pte Ltd, Subsidiaries 36

List Of Figures


Xinjiang Goldwind Science & Technology Co Ltd, Performance Chart (2013 - 2017) 31
Xinjiang Goldwind Science & Technology Co Ltd, Ratio Charts 33
Xinjiang Goldwind Science & Technology Co Ltd, Power, Deals By Year, 2012 to YTD 2018 34
Xinjiang Goldwind Science & Technology Co Ltd, Power, Deals by Type, 2012 to YTD 2018 35

Aslan Pharmaceuticals Pte Ltd (6497) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Aslan Pharmaceuticals Pte Ltd (Aslan), a subsidiary of Aslan Pharmaceuticals Ltd, is a biotechnology company that offers immuno-oncology agents and targeted therapies. The companys pipeline products comprise varlitinib, ASLAN002, ASLAN003

USD 250 View Report

Aslan Pharmaceuticals Pte Ltd - Mergers and Acquisitions (MandA), Partnerships and Alliances and Investment Report

Aslan Pharmaceuticals Pte Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportThe Aslan Pharmaceuticals Pte Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes

USD 350 View Report

Aslan Pharmaceuticals Pte Ltd - Mergers and Acquisitions (MandA), Partnerships and Alliances and Investment Report

Aslan Pharmaceuticals Pte Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportThe Aslan Pharmaceuticals Pte Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes

USD 350 View Report

Aslan Pharmaceuticals Pte Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Aslan Pharmaceuticals Pte Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportMarketlines Aslan Pharmaceuticals Pte Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes

USD 350 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available